Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tuberculosis

Supported pathogenM. tuberculosisMycobacterium tuberculosis

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “tuberculosis”, “mycobacterium tuberculosis”, “tb”, “latent tb”.

Show all 80

Laboratory measurements against M. tuberculosis recorded in ChEMBL.

Show all 54

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against M. tuberculosis that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

M. tuberculosis has 870 repurposing candidates in all. 35 are already listed above, with a registered study for this condition or a laboratory record, so the other 835 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for M. tuberculosis, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started244 of 249 have a start date · most in 2023 (19)
199420102026

  • A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

    NCT07595042 · start 2026-10-30

    Registered record
    Registry ID
    NCT07595042
    Conditions
    Tuberculosis
    Interventions
    Isoniazid; Rifampin; Pyrazinamide; Ethambutol; Rifapentine; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-30
    Completion
    2029-10-22
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionIsoniazid; Rifampin; Pyrazinamide; Ethambutol +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

    NCT07124559 · start 2026-10-15

    Registered record
    Registry ID
    NCT07124559
    Conditions
    Tuberculosis
    Interventions
    Rifapentine; Isoniazid; Dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-15
    Completion
    2028-05-31
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine; Isoniazid; Dolutegravir
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT

    NCT07467252 · start 2026-09

    Registered record
    Registry ID
    NCT07467252
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Pyrazinamide and Hydroxychloroquine (AI-Optimised); Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2028-06
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionPyrazinamide and Hydroxychloroquine (AI-Optimised); Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol)
    PhasePhase 2
    Registry statusNot yet recruiting

  • B-PaLMZ for TB Meningitis

    NCT07227779 · start 2026-07-28

    Registered record
    Registry ID
    NCT07227779
    Conditions
    Tuberculous Meningitis; HIV; Meningitis; TB - Tuberculosis
    Interventions
    BPaLMZ Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-07-28
    Completion
    2030-09-30
    Enrolment
    312

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculous Meningitis; HIV; Meningitis; TB - Tuberculosis
    InterventionBPaLMZ Regimen
    PhasePhase 2
    Registry statusRecruiting

  • Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis

    NCT07773610 · start 2026-07-23

    Registered record
    Registry ID
    NCT07773610
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    TBAJ-587 50 mg; Pretomanid 200mg; Linezolid 600Mg Tab; BTZ-043 250 mg or 500 mg; HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination); Quabodepistat (Q) 30 mg; Ganfeborole 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-23
    Completion
    2027-12-30
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionTBAJ-587 50 mg; Pretomanid 200mg; Linezolid 600Mg Tab; BTZ-043 250 mg or 500 mg +3 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB

    NCT07672405 · start 2026-07-09

    Registered record
    Registry ID
    NCT07672405
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    sorfequiline; Pretomanid; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-07-09
    Completion
    2028-06-24
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    Interventionsorfequiline; Pretomanid; Linezolid
    PhasePhase 2
    Registry statusRecruiting

  • Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan

    NCT07668479 · start 2026-07-01

    Registered record
    Registry ID
    NCT07668479
    Conditions
    Tuberculosis; Tuberculosis Infection, Latent; Tuberculosis, Pulmonary, Drug Sensitive
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2027-08
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Tuberculosis Infection, Latent; Tuberculosis, Pulmonary, Drug Sensitive
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Short-Course Regimens for DS-PTB in AIDS Patients

    NCT07608172 · start 2026-05-25

    Registered record
    Registry ID
    NCT07608172
    Conditions
    Tuberculosis in HIV-infected Individuals; Drug Susceptible Pulmonary Tuberculosis
    Interventions
    2HPMZ/2HPM; 2HRZE/4HR
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-05-25
    Completion
    2028-12-31
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis in HIV-infected Individuals; Drug Susceptible Pulmonary Tuberculosis
    Intervention2HPMZ/2HPM; 2HRZE/4HR
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB

    NCT06568484 · start 2026-05-08

    Registered record
    Registry ID
    NCT06568484
    Conditions
    Tuberculosis, Latent
    Interventions
    Bedaquiline; Isoniazid, rifapentine; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-05-08
    Completion
    2027-09
    Enrolment
    2,530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Latent
    InterventionBedaquiline; Isoniazid, rifapentine; Levofloxacin
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis

    NCT07517445 · start 2026-04-17

    Registered record
    Registry ID
    NCT07517445
    Conditions
    Drug Susceptible Pulmonary Tuberculosis
    Interventions
    Bedaquiline, pretomanid, linezolid; Bedaquiline, pretomanid, linezolid; Bedaquiline, pretomanid, linezolid; Nicotinamide (NAM)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2026-04-17
    Completion
    2027-06-14
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Susceptible Pulmonary Tuberculosis
    InterventionBedaquiline, pretomanid, linezolid; Bedaquiline, pretomanid, linezolid; Bedaquiline, pretomanid, linezolid; Nicotinamide (NAM)
    PhasePhase 2
    Registry statusSuspended

  • Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis

    NCT07525427 · start 2026-04-14

    Registered record
    Registry ID
    NCT07525427
    Conditions
    Drug Susceptible Pulmonary Tuberculosis
    Interventions
    Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-04-14
    Completion
    2026-11-05
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Susceptible Pulmonary Tuberculosis
    InterventionBedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09 +1 more
    PhasePhase 2
    Registry statusRecruiting

  • Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis

    NCT06590428 · start 2026-04-07

    Registered record
    Registry ID
    NCT06590428
    Conditions
    Rifampin-resistant Tuberculosis; Drug-resistant Tuberculosis
    Interventions
    Therapeutic Drug Monitoring for Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-04-07
    Completion
    2029-12
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRifampin-resistant Tuberculosis; Drug-resistant Tuberculosis
    InterventionTherapeutic Drug Monitoring for Linezolid
    PhaseNot applicable
    Registry statusRecruiting

  • Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis

    NCT07350174 · start 2026-03-30

    Registered record
    Registry ID
    NCT07350174
    Conditions
    Tuberculosis Meningitis
    Interventions
    HRZE; HRZE plus Alpe375; HRZE plus AlpE500; HRZE plus AlpE625
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03-30
    Completion
    2028-10-30
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis Meningitis
    InterventionHRZE; HRZE plus Alpe375; HRZE plus AlpE500; HRZE plus AlpE625
    PhasePhase 2
    Registry statusNot yet recruiting

  • Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)

    NCT07393438 · start 2026-02-21

    Registered record
    Registry ID
    NCT07393438
    Conditions
    Multidrug-Resistant Tuberculosis; Rifampicin-resistant Tuberculosis; MDR-TB; RR-TB
    Interventions
    Acetohydroxamic Acid; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-02-21
    Completion
    2028-11-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug-Resistant Tuberculosis; Rifampicin-resistant Tuberculosis; MDR-TB; RR-TB
    InterventionAcetohydroxamic Acid; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease

    NCT07118696 · start 2026-02-01

    Registered record
    Registry ID
    NCT07118696
    Conditions
    Pulmonary TB
    Interventions
    Extra 600mg of Rifampicin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-02-01
    Completion
    2030-01-31
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary TB
    InterventionExtra 600mg of Rifampicin; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting